129 related articles for article (PubMed ID: 37105784)
1. An analysis of time to treatment in patients with pancreatic adenocarcinoma.
Sugumar K; Gendi S; Quereshy HA; Gupta S; Hue JJ; Rothermel LD; Ocuin LM; Ammori JB; Hardacre JM; Winter JM
Surgery; 2023 Jul; 174(1):83-90. PubMed ID: 37105784
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal comparison of IL-6, IL-10, and IL-12 cytokine profiles in adult and childhood-onset systemic lupus erythematosus.
Peliçari KO; Postal M; Sinicato NA; Londe AC; Fernandes PT; Marini R; Costallat LTL; Appenzeller S
J Transl Autoimmun; 2022; 5():100158. PubMed ID: 36683864
[TBL] [Abstract][Full Text] [Related]
3. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma.
Murphy MM; Simons JP; Ng SC; McDade TP; Smith JK; Shah SA; Zhou Z; Earle CC; Tseng JF
Ann Surg Oncol; 2009 Nov; 16(11):2968-77. PubMed ID: 19669839
[TBL] [Abstract][Full Text] [Related]
4. Care pathway of patients with metastatic pancreatic cancer in daily practice in France: Results from the REPERE national survey.
Hammel P; Coriat R; Lledo G; de Bausset M; Selosse M; Obled S; Bonnetain F
Bull Cancer; 2017 Apr; 104(4):321-331. PubMed ID: 28087054
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Survival among Early Onset Pancreatic Adenocarcinoma Patients A Tertiary Care Center Experience.
Alkashash AM; Elsebaie MA; Bikhet MH; Morsi M; Paluri RK
Chirurgia (Bucur); 2021; 116(1):24-33. PubMed ID: 33638323
[TBL] [Abstract][Full Text] [Related]
6. Oncology Navigation Decreases Time to Treatment in Patients with Pancreatic Malignancy.
Enomoto LM; Fenstermaker J; Desnoyers RJ; Pasche BC; Blackstock AW; Howerton RM; Clark CJ; Levine EA; Shen P
Ann Surg Oncol; 2019 May; 26(5):1512-1518. PubMed ID: 30652224
[TBL] [Abstract][Full Text] [Related]
7. Survival analysis of veteran patients with pancreatic cancer.
Kim D; Zhu H; Nassri A; Mokdad A; Kukreja S; Polanco P; Huerta S; Ramzan Z
J Dig Dis; 2016 Jun; 17(6):399-407. PubMed ID: 27235863
[TBL] [Abstract][Full Text] [Related]
8. A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer.
Abdel-Rahman O; Xu Y; Tang PA; Lee-Ying RM; Cheung WY
Cancer Med; 2018 Dec; 7(12):6385-6392. PubMed ID: 30378285
[TBL] [Abstract][Full Text] [Related]
9. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups.
Chang KJ; Parasher G; Christie C; Largent J; Anton-Culver H
Cancer; 2005 Jan; 103(2):349-57. PubMed ID: 15593353
[TBL] [Abstract][Full Text] [Related]
10. Impact of Race, Insurance Status, and Primary Language on Presentation, Treatment, and Outcomes of Patients with Pancreatic Adenocarcinoma at a Safety-Net Hospital.
Sridhar P; Misir P; Kwak H; deGeus SW; Drake FT; Cassidy MR; McAneny DA; Tseng JF; Sachs TE
J Am Coll Surg; 2019 Oct; 229(4):389-396. PubMed ID: 31212101
[TBL] [Abstract][Full Text] [Related]
11. Exocrine Pancreatic carcinoma in Tunisia: A retrospective study about 158 cases.
El Guesmi S; Ben Nasr S; Afrit M; Labidi S; Boussen H
Tunis Med; 2015 Feb; 93(2):73-5. PubMed ID: 26337302
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer.
Gobbi PG; Bergonzi M; Comelli M; Villano L; Pozzoli D; Vanoli A; Dionigi P
Cancer Epidemiol; 2013 Apr; 37(2):186-90. PubMed ID: 23369450
[TBL] [Abstract][Full Text] [Related]
13. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis.
Hernandez JM; Tsalatsanis A; Humphries LA; Miladinovic B; Djulbegovic B; Velanovich V
Ann Surg; 2014 Jun; 259(6):1208-14. PubMed ID: 24169177
[TBL] [Abstract][Full Text] [Related]
14. Very Early Onset Pancreatic Adenocarcinoma - Clinical Presentation, Risk Factors and Therapeutic Options.
Bunduc Ș; Iacob R; Costache R; Stoica B; Radu C; Gheorghe C
Chirurgia (Bucur); 2018; 113(3):405-411. PubMed ID: 29981672
[No Abstract] [Full Text] [Related]
15. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma.
Pendurthi TK; Hoffman JP; Ross E; Johnson DE; Eisenberg BL
Am Surg; 1998 Jul; 64(7):686-92. PubMed ID: 9655283
[TBL] [Abstract][Full Text] [Related]
16. [Pancreatic cancer that was diagnosed two years after palliative treatment].
Anía Lahuerta MA; Villalta Cabero J
An Med Interna; 2006 Dec; 23(12):585-7. PubMed ID: 17371147
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer.
Raptis DA; Fessas C; Belasyse-Smith P; Kurzawinski TR
Surgeon; 2010 Oct; 8(5):239-46. PubMed ID: 20709279
[TBL] [Abstract][Full Text] [Related]
18. Trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma.
Salami A; Obaid T; Joshi ART
Am J Surg; 2019 Jan; 217(1):103-107. PubMed ID: 29807632
[TBL] [Abstract][Full Text] [Related]
19. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy.
Kasumova GG; Eskander MF; de Geus SWL; Neto MM; Tabatabaie O; Ng SC; Miksad RA; Mahadevan A; Rodrigue JR; Tseng JF
Surgery; 2017 Aug; 162(2):275-284. PubMed ID: 28487044
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic delay does not influence survival of pancreatic cancer patients.
Stornello C; Archibugi L; Stigliano S; Vanella G; Graglia B; Capalbo C; Nigri G; Capurso G
United European Gastroenterol J; 2020 Feb; 8(1):81-90. PubMed ID: 32213057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
